RxDoctor Payments Data

Stephen Conrad, MD

Internal Medicine · Media, PANPI 1477643609

Payments from drug & device makers

$297in general payments, 2019–2025

Across 10 payments — averaging $29.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$122
  • AbbVie$64
  • Abbott$44
  • AstraZeneca$33
  • Pfizer$20
  • GSK$14

What the payments were for

  • Food & beverage$297100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis1$122
AbbVie(2 entities)3$64
Abbott2$44
AstraZeneca2$33
Pfizer1$20
GSK1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$297 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$144,576
Medicare patients
359
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$157,754
JanuviaSitagliptin Phosphate55$46,736
JardianceEmpagliflozin50$44,715
TrulicityDulaglutide23$31,053
OzempicSemaglutide21$29,738
MyrbetriqMirabegron38$15,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,991
Cinacalcet Hcl17$13,519
XareltoRivaroxaban13$11,173
Fluticasone-SalmeterolFluticasone Propion/Salmeterol61$10,112
Combivent RespimatIpratropium/Albuterol Sulfate21$9,976
ZenpepLipase/Protease/Amylase19$9,942
Cyclosporine32$9,275
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$7,984
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$157,754231 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$14$26,46247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →